Advertisement

Advertisement

PRLD Stock Latest News

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

The FlyPrelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

Prelude Therapeutics Shareholders Back Leadership and Governance

PremiumCompany Announcements

Prelude Therapeutics Shareholders Back Leadership and Governance

2M ago

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

PremiumThe Fly

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

3M ago

Prelude Therapeutics Launches Phase 1 Trial and Extends Runway

PremiumCompany Announcements

Prelude Therapeutics Launches Phase 1 Trial and Extends Runway

3M ago

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

PremiumThe Fly

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

3M ago

Prelude Therapeutics initiated with a Buy at D. Boral Capital

PremiumThe FlyPrelude Therapeutics initiated with a Buy at D. Boral Capital

3M ago

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

Company Announcements

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

3M ago

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

The Fly

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

3M ago

Prelude Therapeutics Prices Public Offering to Extend Runway

PremiumCompany Announcements

Prelude Therapeutics Prices Public Offering to Extend Runway

3M ago

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

PremiumCompany Announcements

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

3M ago

Prelude Therapeutics presents new preclinical data from PRT13722 study

PremiumThe Fly

Prelude Therapeutics presents new preclinical data from PRT13722 study

3M ago

Prelude Therapeutics Appoints Veteran Oncologist as New CMO

PremiumCompany Announcements

Prelude Therapeutics Appoints Veteran Oncologist as New CMO

4M ago

Prelude Therapeutics announces Charles Morris as chief medical officer

PremiumThe FlyPrelude Therapeutics announces Charles Morris as chief medical officer

4M ago

Prelude Therapeutics management to meet with Citizens

The Fly

Prelude Therapeutics management to meet with Citizens

5M ago

Prelude Therapeutics Establishes New ATM Equity Offering Facility

Company Announcements

Prelude Therapeutics Establishes New ATM Equity Offering Facility

5M ago

Prelude Therapeutics price target raised to $6 from $3 at Citizens

PremiumThe Fly

Prelude Therapeutics price target raised to $6 from $3 at Citizens

5M ago

Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

PremiumCompany Announcements

Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

5M ago

Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year

PremiumThe Fly

Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year

5M ago

Prelude Therapeutics sees cash runway into 2Q27

PremiumThe Fly

Prelude Therapeutics sees cash runway into 2Q27

5M ago

Prelude Therapeutics Wins FDA IND Clearance for PRT12396

PremiumCompany AnnouncementsPrelude Therapeutics Wins FDA IND Clearance for PRT12396

6M ago

Prelude receives FDA clearance for investigational IND for PRT12396

The Fly

Prelude receives FDA clearance for investigational IND for PRT12396

6M ago

Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology

Company Announcements

Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >